Hjem › Multipelt myelom › Kentucky
Multipelt myelom kliniske forsøg i Kentucky
15 studier for Multipelt myelom søger deltagere på steder i Kentucky.
Byer i Kentucky
Officiel studietekst (engelsk)
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Louisville
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 29. sep. 2026 · NCT07391657A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Norton Cancer Institute, Louisville
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT07518186A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- Norton Cancer Institute, Louisville
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT07258511A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- Norton Cancer Institute, Louisville
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT04634552A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Norton Cancer Institute, Louisville
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT05552222Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
- Norton Healthcare, Inc., Louisville
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 17. sep. 2026 · NCT04879043Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Norton Women's and Children's Hospital, Louisville
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 14. sep. 2026 · NCT06297226Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- CommonSpirit Saint Joseph Hospital - Bardstown, Bardstown
- Commonwealth Cancer Center-Corbin, Corbin
- Saint Joseph Radiation Oncology Resource Center, Lexington
- og 3 flere
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 19. aug. 2026 · NCT04566328Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Louisville
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 14. aug. 2026 · NCT07764978A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
- Norton Cancer Institute St. Matthews, Louisville
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 12. aug. 2026 · NCT07280013Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Flaget Memorial Hospital, Bardstown
- Commonwealth Cancer Center-Corbin, Corbin
- Saint Joseph Hospital, Lexington
- og 4 flere
RekruttererFase 3
Alle aldre · Alle køn · Opdateret 10. jun. 2026 · NCT05561387A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
- Norton Cancer Institute, Louisville
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 13. maj 2026 · NCT05828511Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
- Norton Cancer Institute, Louisville
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 20. apr. 2026 · NCT03761108cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Baptist Corbin, Corbin
- Baptist Hardin, Elizabethtown
- Baptist Lexington, Lexington
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
Alder 40 og opefter · Alle køn · Opdateret 20. jan. 2026 · NCT05366881CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
- University of Kentucky/ Markey Cancer Center, Lexington
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2025 · NCT05722418Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.